Docosahexaenoic Acid Supplementation And Cognitive Decline In Alzheimer Disease: A Randomized Trial
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 295 |
| Sex | Both Genders |
| Age Range | 65+ |
| Body Types | Overweight, Average |
2,000mg DHA from algae for 18 months failed to significantly delay symptoms associated with Alzheimer's disease or reduce the rate of cognitive decline as assessed by CDR and ADAS-cog rating scales. Similarly, the rate of brain atrophy was not affected.
